Arabic Arabic English English French French German German
dark

JanOne Selects CPC Clinical Research as Trial Manager for Phase 2b Study of JAN101 for Peripheral Artery Disease Patients

JanOne Inc. today announced that it has selected CPC Clinical Research (CPC),a full-service academic research organization (ARO), as manager for its upcoming Phase 2b clinical trial of lead product candidate JAN101 for treating Peripheral Artery Disease (PAD). Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Hiscox boss Bronek Masojada to retire – successor revealed

Next Post

Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update

Related Posts
Total
0
Share